Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 1/20 | 0.64 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | CCKBR | P32239 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27990536 | 0.98 | CCR6 (0.66) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL14476880 | 0.97 | CCR6 (0.63) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL15508590 | 0.95 | CCR6 (0.63) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL17275425 | 0.94 | CCR6 (0.61) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL18057682 | 0.94 | CCR6 (0.60) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL13661575 | 0.93 | CCR6 (0.64) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL10822804 | 0.92 | CCR6 (0.62) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL15355992 | 0.92 | CCR6 (0.59) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL10822929 | 0.92 | CCR6 (0.62) | CCR6PAX8ALDH1A1CYP3A4TSHR | |
| SCHEMBL13661572 | 0.92 | CCR6 (0.62) | CCR6PAX8ALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673914-B2 | Peptide therapies for reduction of macular thickening | Allegro Pharmaceuticals, LLC (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673914-B2 | Peptide therapies for reduction of macular thickening | ITGB3, ITGB5, ITGAV | CCR6 103/4885PAX8 3889/4885ALDH1A1 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.